ORKA-001 also met secondary endpoints at 16 weeks, and updated data support the potential for once-yearly dosing ...

A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the ...

Available evidence suggests GLP-1 receptor agonists warrant consideration as an adjunct to conventional treatments for ...

Medically reviewed by Casey Gallagher, MD Key Takeaways Clobex spray is a powerful corticosteroid that can clear psoriasis ...

April 27 (Reuters) - Oruka Therapeutics said on Monday that interim results showed its experimental drug helped clear psoriasis within 16 weeks, meeting the main goal of a mid-stage study and sending ...

(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the once-daily pill helped patients achieve clear or almost clear skin. The ...

A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical ...

Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading ...

If youre living with psoriasis, you may have noticed that your treatment plan changes over time sometimes for the sake of safety and side effects, and sometimes because a treatment stops working as ...

Johnson & Johnson (JNJ) introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE offers an innovative ...

Artelo Biosciences, Inc. announced promising findings from new research published in the Journal of Investigative Dermatology regarding its lead drug candidate ART26.12, a small-molecule inhibitor of ...